{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:08:29Z","timestamp":1747159709914,"version":"3.40.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejpb.2024.114459","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:44:54Z","timestamp":1724366694000},"page":"114459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Arg-Specific serine Protease-Targeted edoxaban tosylate monohydrate-Poly (lactic-co-glycolic acid) Nanoparticles: Investigating Stuart-Prower factor targeting and intestinal distribution through Ex-Vivo fluorescent visualization"],"prefix":"10.1016","volume":"203","author":[{"given":"Pavazhaviji","family":"Pazhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Prakash Dharmian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-2552","authenticated-orcid":false,"given":"Somasundaram","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavithra","family":"pazhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya","family":"Vara Prasad Medapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114459_b0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2022","journal-title":"Nature Reviews Cardiol."},{"key":"10.1016\/j.ejpb.2024.114459_b0010","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.3390\/ijms24043169","article-title":"A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology","volume":"24","author":"Pastori","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114459_b0015","article-title":"Abciximab coated albumin nanoparticles of rutin for improved and targeted antithrombotic effect","volume":"76","author":"Rout","year":"2022","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.ejpb.2024.114459_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28033","article-title":"Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism","volume":"6","author":"Fang","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejpb.2024.114459_b0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejim.2023.08.007","article-title":"Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants","volume":"118","author":"Kaneda","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejpb.2024.114459_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13065-022-00890-2","article-title":"Development and validation of a novel spectrofluorimetric method of oral anticoagulant edoxaban via derivatization with 9-fluorenyl methyl chloroformate: Green assessment of the method by Eco-Scale and Complexgapi","volume":"16","author":"Rizk","year":"2022","journal-title":"BMC Chem."},{"key":"10.1016\/j.ejpb.2024.114459_b0035","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-23-0291","article-title":"Clinical characteristics and outcomes of patients with venous thromboembolism receiving edoxaban in the real world","author":"Yamashita","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.ejpb.2024.114459_b0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41405-023-00164-6","article-title":"Edoxaban use in the context of dental procedures: Analysis from the emit-AF\/VTE database","volume":"9","author":"Chen","year":"2023","journal-title":"BDJ Open."},{"key":"10.1016\/j.ejpb.2024.114459_b0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-023-02926-3","article-title":"Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies","author":"Fredman","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ejpb.2024.114459_b0050","first-page":"1","article-title":"Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia Region, Drugs","volume":"12","author":"Bimbo Diaz","year":"2023","journal-title":"Context"},{"key":"10.1016\/j.ejpb.2024.114459_b0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11912-023-01428-y","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism","volume":"25","author":"Masini","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejpb.2024.114459_b0060","article-title":"Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment","volume":"34","author":"Liu","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejpb.2024.114459_b0065","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1038\/s41596-023-00843-6","article-title":"Development of ionic liquid-coated plga nanoparticles for applications in intravenous drug delivery","volume":"18","author":"Dasanayake","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2024.114459_b0070","article-title":"Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs","volume":"24","author":"Mahar","year":"2023","journal-title":"AAPS Pharm SciTech."},{"key":"10.1016\/j.ejpb.2024.114459_b0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/1061186X.2023.2199350","article-title":"Cetuximab-conjugated plga nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer","volume":"31","author":"Kumari","year":"2023","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2024.114459_b0080","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1021\/acsomega.3c00738","article-title":"Synthesis and evaluation of BSA-loaded plga\u2013chitosan composite nanoparticles for the protein-based drug delivery system","volume":"8","author":"Gaur","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2024.114459_b0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/1061186X.2022.2148679","article-title":"EPCAM aptamer activated 5-fu-loaded plga nanoparticles in CRC treatment; in vitro and in vivo study","volume":"31","author":"Yavari","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2024.114459_b0090","doi-asserted-by":"crossref","unstructured":"P. Reddy, V.S. Jagarlapudi, C. Sekaran, Determination of edoxaban in bulk and in tablet dosage form by stability indicating high-performance liquid chromatography, Pharm Sci. 22 (2016) 35\u201341. 10.15171\/ps.2016.07.","DOI":"10.15171\/PS.2016.07"},{"key":"10.1016\/j.ejpb.2024.114459_b0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.colsurfb.2012.10.021","article-title":"The characteristics and improved intestinal permeability of vancomycin plga-nanoparticles as colloidal drug delivery system","volume":"103","author":"Zakeri-Milani","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2024.114459_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120617","article-title":"Paeonol-loaded plga nanoparticles as an oral drug delivery system: Design, optimization and evaluation","volume":"602","author":"Wang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114459_b0105","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/21691401.2016.1276920","article-title":"Mishra, Development and characterization of polymer lipid hybrid nanoparticles for oral delivery of LMWH","volume":"45","author":"Hallan","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114459_b0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijbiomac.2021.02.093","article-title":"Low molecular weight chitosan-cyanocobalamin nanoparticles for controlled delivery of ciprofloxacin: Preparation and evaluation","volume":"176","author":"Hosseini-Ashtiani","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2024.114459_b0115","doi-asserted-by":"crossref","unstructured":"Mohd. Imran, M. Sajwan, B. Alsuwayt, M. Asif, Synthesis, characterization and anticoagulant activity of chitosan derivatives, Saudi Pharm. J. 28 (2020) 25\u201332. 10.1016\/j.jsps.2019.11.003.","DOI":"10.1016\/j.jsps.2019.11.003"},{"key":"10.1016\/j.ejpb.2024.114459_b0120","first-page":"1","article-title":"Formulation and optimization of polymeric nanoparticles for intranasal delivery of Lorazepam using box-behnken design:in vitroandin vivoevaluation","volume":"2014","author":"Sharma","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ejpb.2024.114459_b0125","doi-asserted-by":"crossref","unstructured":"S.A. Mousa, In vivo models for the evaluation of antithrombotics and thrombolytics, Anticoagulants, Antiplatelets, and Thrombolytics. (2010) 29\u2013107. 10.1007\/978-1-60761-803-4_2.","DOI":"10.1007\/978-1-60761-803-4_2"},{"key":"10.1016\/j.ejpb.2024.114459_b0130","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/ijms24032569","article-title":"Thrombosis models: An overview of common in vivo and in vitro models of thrombosis","volume":"24","author":"Ayyoub","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114459_b0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/15353702221118533","article-title":"Establishment of a mouse model for ovarian cancer\u2013associated venous thromboembolism","volume":"248","author":"Ma","year":"2022","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejpb.2024.114459_b0140","first-page":"607","article-title":"Development of lipid\u2013polymer hybrid nanoparticles for improving oral absorption of enoxaparin","volume":"12","author":"Tang","year":"2020","journal-title":"Pharm."},{"key":"10.1016\/j.ejpb.2024.114459_b0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/jfb13030141","article-title":"Preparation of fluorescently labeled chitosan-quercetin drug-loaded nanoparticles with excellent antibacterial properties","volume":"13","author":"Zhou","year":"2022","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.ejpb.2024.114459_b0150","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/17425247.2019.1690452","article-title":"in vivo biodistribution of venlafaxine-plga nanoparticles for Brain Delivery: Plain vs. functionalized nanoparticles","volume":"16","author":"Cayero-Otero","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114459_b0155","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.2147\/IJN.S172230","article-title":"Low-molecular-weight sulfonated chitosan as template for anticoagulant nanoparticles","volume":"13","author":"Heise","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2024.114459_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/4925495","article-title":"Characterization of PCL and chitosan nanoparticles as carriers of enoxaparin and its antithrombotic effect in animal models of venous thrombosis","volume":"2017","author":"Prado","year":"2017","journal-title":"J. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114459_b0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/08982104.2019.1576732","article-title":"Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases","volume":"29","author":"Abouhussein","year":"2019","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejpb.2024.114459_b0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11239-019-02022-5","article-title":"Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect","volume":"49","author":"Anwer","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ejpb.2024.114459_b0175","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/acs.biomac.1c00303","article-title":"Designing s100a9-targeted plant virus nanoparticles to target deep vein thrombosis","volume":"22","author":"Park","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2024.114459_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111427","article-title":"Use of MPEG-plga nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies","volume":"118","author":"Hasanpour","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejpb.2024.114459_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01932691.2024.2371953","article-title":"Anti \u2013 intercellular adhesion molecule-1(icam-1) nanoparticles for damaged endothelium to treat venous thromboembolism","author":"Pazhani","year":"2024","journal-title":"J. Dispers. Sci. Technol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:19:55Z","timestamp":1730092795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124002856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"alternative-id":["S0939641124002856"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114459","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arg-Specific serine Protease-Targeted edoxaban tosylate monohydrate-Poly (lactic-co-glycolic acid) Nanoparticles: Investigating Stuart-Prower factor targeting and intestinal distribution through Ex-Vivo fluorescent visualization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114459"}}